Ahmedabad-based Zydus Lifesciences said on Tuesday that a new drug application for its oral drug Desidustat used in treating anaemia in chronic kidney disease (CKD) patients had been accepted by the National Medical Products Administration of China (NMPA).
In 2020, CMS International Development and Management Ltd, a wholly-owned subsidiary of China Medical System Holdings Ltd obtained an exclusive license for the product from Zydus.
CKD involves a gradual loss of functioning of kidneys and eventually leads to kidney failure.
As we enter February 2024, the Hong Kong market has shown resilience, with investors navigating through economic headwinds and finding pockets of growth amidst global uncertainty.
/PRNewswire/ Recently, Morgan Stanley Capital International (MSCI), the world s largest index provider, has updated the Environmental, Social and Governance.
/PRNewswire/ Recently, Morgan Stanley Capital International (MSCI), the world s largest index provider, has updated the Environmental, Social and Governance.